Bausch Health Companies Inc. (BHC)

Market Cap	1.88B
Revenue (ttm)	9.63B
Net Income (ttm)	-46.00M
Shares Out	369.51M
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	1.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,207,125
Open	4.595
Previous Close	4.500
Day's Range	4.565 - 5.260
52-Week Range	3.960 - 9.850
Beta	0.43
Analysts	Hold
Price Target	7.20 (+56.69%)
Earnings Date	Apr 30, 2025

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas Appio
• Employees: 20,700
• Stock Exchange: NYSE
• Ticker Symbol: BHC
• Website: https://www.bauschhealth.com

Financial Performance

In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $7.2, which is an increase of 56.69% from the latest price.

Price Target

$7.2

(56.69% upside)

Analyst Consensus: Hold